Macular Corneal Dystrophy Type 1Symptoms, Doctors, Treatments, Advances & More
Learn About Macular Corneal Dystrophy Type 1
Johns Hopkins Community Physicians - Water's Edge
Allen Eghrari is an Ophthalmologist practicing medicine in Belcamp, Maryland. Dr. Eghrari is rated as an Elite provider by MediFind in the treatment of Macular Corneal Dystrophy Type 1. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Fuchs Dystrophy, Macular Corneal Dystrophy Type 1, Ebola Virus Disease, Corneal Transplant, and Cataract Removal. Dr. Eghrari is board certified in American Board Of Ophthalmology. Dr. Eghrari is currently accepting new patients.
The Johns Hopkins Hospital
John Gottsch is an Ophthalmologist practicing medicine in Baltimore, Maryland. Dr. Gottsch is rated as an Elite provider by MediFind in the treatment of Macular Corneal Dystrophy Type 1. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Macular Corneal Dystrophy Type 1, Fuchs Dystrophy, Corneal Dystrophy and Perceptive Deafness, Cataract, and Corneal Transplant. Dr. Gottsch is board certified in American Board Of Ophthalmology. Dr. Gottsch is currently accepting new patients.
Corneal Disease And Surgery Clinic
David Hwang is an Ophthalmologist practicing medicine in San Francisco, California. Dr. Hwang is rated as an Elite provider by MediFind in the treatment of Macular Corneal Dystrophy Type 1. He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Fuchs Dystrophy, Macular Corneal Dystrophy Type 1, Keratoconus, Corneal Dystrophy and Perceptive Deafness, and Corneal Transplant. Dr. Hwang is board certified in American Board Of Ophthalmology, Ophthalmology. Dr. Hwang is currently accepting new patients.
Summary: This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.
Summary: Fuchs endothelial corneal dystrophy (FECD) is the leading indication for corneal transplantation worldwide. It is characterized by the accumulation of guttae and progressive loss of corneal endothelial cells, leading to corneal edema and visual impairment. Endothelial keratoplasty remains the standard treatment; however, graft shortages have driven the development of cell-based therapies involving...